diaDexus, Inc. to Present at the Leerink Swann Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013 (GLOBE NEWSWIRE) -- diaDexus, Inc.
(OTCQB:DDXS), a company developing and commercializing proprietary
cardiovascular diagnostic products, today announced that Brian E. Ward, Ph.D.,
Chief Executive Officer, is scheduled to present at the Leerink Swann Global
Healthcare Conference in New York. Dr. Ward will provide a corporate overview
and update and will be available to conduct one-on-one meetings with
Event: Leerink Swann Global Healthcare Conference
Date: February 14, 2013
Time: 1:30 pm ET
A live webcast of the presentation will be accessible on diaDexus' website at
www.diadexus.com. Please go to the website a few minutes early, as it may be
necessary to download audio software to hear the presentation. A replay of the
webcast will also be available after the conference concludes.
About diaDexus, Inc.
diaDexus, Inc., based in South San Francisco, California, develops and
commercializes proprietary cardiovascular diagnostic products addressing unmet
needs in cardiovascular disease. The company's PLAC® Test ELISA Kit is the
only blood test cleared by the FDA to aid in predicting risk for both coronary
heart disease and ischemic stroke associated with atherosclerosis, the #1 and
#3 causes of death, respectively, in the United States. The company's PLAC®
Test for Lp-PLA Activity, a CE-marked test, is an indicator of
atherosclerotic cardiovascular disease, the #1 cause of death in Europe.
diaDexus is ISO 13485 certified and is manufacturing the PLAC Test for
Lp-PLA Activity on-site. For more information, please visit the company's
website at www.diaDexus.com.
CONTACT: Company Contacts:
Brian E. Ward, Ph.D., CEO
Jean-Frederic Viret, Ph.D., CFO
The Ruth Group
Press spacebar to pause and continue. Press esc to stop.